Mark A. Rubin, MD, Professor, Principal Investigator, and Director of the Department for BioMedical Research
(DBMR), University of Bern, Switzerland. Prof. Mark Rubin is a recognized world-renown leader in prostate
cancer genomics and pathology, and precision medicine. Dr. Rubin’s laboratory led a series of landmark
studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive
different types of this cancer. Furthermore, Prof. Rubin has translated many of his genomic discoveries into
clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer.
Prof. Rubin founded the Englander Institute for Precision Medicine and, more recently, the Bern Center for
Precision Medicine (BCPM)